Skip to main content

Advertisement

Table 2 Association of NNMT expression with clinicopathological characteristics in 82 breast cancer patients with a chemotherapy efficacy record

From: Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

Patient characteristics n NNMTh (%) Pearson’s χ2 P
Total 82 38 (46.3)   
Age (years)
Median = 50
≤ 50 (36) 19 (52.8) 1.069 0.301
> 50 (46) 36 (41.3)
ER Positive (58) 24 (41.4) 1.962 0.161
Negative (24) 14 (58.3)
PR Positive (53) 23 (43.4) 0.523 0.470
Negative (29) 15 (51.7)
HER-2 Positive (43) 22 (51.2) 1.417 0.232
Negative (37) 14 (37.8)
Ki-67 Positive (35) 15 (42.9) 0.081 0.776
Negative (39) 18 (46.2)
Molecular subtype    3.364 0.339
 Luminal A 20 6 (30.0)
 Luminal B 42 21 (50.0)
 ERBB2 13 6 (46.2)
 Basal-like 6 4 (66.7)
TNM 0.115 0.990
 0 0 0 (0)
 I 27 13 (48.1)
 II 39 18 (46.2)
 III 14 6 (42.9)
 IV 2 1 (50.0)
TNM2 0.393 0.530
 0 + I + II 63 28 (44.4)
 III + IV 19 10 (52.6)
Primary tumor size 1.387 0.709
 Tis 0 0 (0)
 T1 35 18 (51.4)
 T2 39 16 (41.0)
 T3 5 3 (60.0)
 T4 3 1 (33.3)
Lymph node metastasis 2.980 0.395
 N0 49 23 (46.9)
 N1 19 9 (47.4)
 N2 8 5 (62.5)
 N3 6 1 (16.7)
Distant metastasis 1.770 0.183
 M0 80 38 (47.5)
 M1 2 0 (0)
Chemotherapy response 4.807 0.028
 CR+PR 32 10 (31.3)
 SD+PD 50 28 (56.0)
  1. NNMTh NNMT high expression, CR complete response, PR partial response, SD stable disease, PD progressive disease